ArticleTranslational cancer research2020
Potential of microRNA expression profile in predicting renal impairment risk in multiple myeloma patients.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Potential Clinical Role of LncRNA miR503HG in Multiple Myeloma and its Effect on the Proliferation and Adhesion of Myeloma Cells.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- Comprehensive analysis of lncRNA and miRNA expression profiles and ceRNA network construction in negative pressure wound therapy.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the correlation of microRNA (miRNA) expression profile with renal impairment (RI) risk in multiple myeloma (MM) patients.
methodsPlasma cell samples were isolated from bone marrows of 20 RI-MM patients and 20 non-RI-MM patients, and then proposed to microarray assay. Then 5 candidate miRNAs were selected and further validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in plasma cell samples from bone marrows of 60 RI-MM patients and 60 non-RI-MM patients.
resultsPrincipal component analysis and heatmap analysis revealed that miRNA expression profile could clearly distinguish RI-MM patients from non-RI-MM patients, further Valcano plots identified 28 upregulated and 13 downregulated miRNAs in RI-MM patients compared to non-RI-MM patients, and enrichment analysis observed that these dysregulated miRNAs were enriched in renal/inflammatory/apoptosis pathways and renal/inflammatory diseases. Subsequent RT-qPCR validation discovered that miR-103a-3p, miR-449c-5p and let-7a-5p were greatly increased, while miR-877-5p and miR-455-3p were dramatically decreased in RI-MM patients compared to non-RI-MM patients, and all of them could predict RI risk in MM patients by receiver operating characteristic (ROC) curve analysis. Most importantly, the combination of these five miRNAs presented with a great predictive value for RI risk in MM patients with an area under the curve (AUC) of 0.934, 95% CI: 0.895-0.974.
conclusionsMiRNA expression profile is closely implicated in the RI development, and miR-103a-3p, miR-449c-5p, miR-877-5p, miR-455-3p and let-7a-5p may serve as novel biomarkers for RI risk in MM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.